# Evolocumab bij HIV met dyslipidemie: BEIJERINCK gerandomiseerde studie

*geplaatst 2020-05-26 · Cholesterol · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2020.03.025 · https://hartvaat.nl/2020/05/26/evolocumab-bij-hiv-met-dyslipidemie-beijerinck-gerandomiseerde-studie/*

BEIJERINCK gerandomiseerde studie van evolocumab bij HIV-patiënten met dyslipidemie. Eerste PCSK9-remmer trial specifiek bij HIV.

## English: Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.

The BEIJERINCK trial demonstrated that evolocumab effectively lowers LDL cholesterol in people living with HIV and dyslipidemia, providing the first randomized evidence for PCSK9 inhibitor use in HIV-associated cardiovascular risk.

## Abstract (original, from the publication)

BACKGROUND: People living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens. OBJECTIVES: This study sought to evaluate the efficacy and safety of evolocumab in dyslipidemic PLHIV. METHODS: BEIJERINCK (EvolocumaB Effect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) is a randomized, double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally-tolerated statin therapy. The primary endpoint was the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary endpoints included achievement of LDL-C <70 mg/dl and percent change in other plasma lipid and lipoprotein levels. Treatment-emergent adverse events were also examined. RESULTS: A total of 464 patients were analyzed (mean age of 56.4 years, 82.5% male, mean duration with HIV of 17.4 years). ASCVD was documented in 35.6% of patients, and statin intolerance/contraindications to statin use were present in 20.7% of patients. Evolocumab reduced LDL-C by 56.9% (95% confidence interval: 61.6% to 52.3%) from baseline to week 24 versus placebo. An LDL-C level of <70 mg/dl was achieved in 73.3% of patients in the evolocumab group versus 7.9% in the placebo group. Evolocumab also significantly reduced other atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) (all p < 0.0001). Evolocumab was well tolerated, and treatment-emergent adverse events patient incidence was similar among evolocumab and placebo groups. CONCLUSIONS: Evolocumab was safe and significantly reduced lipid levels in dyslipidemic PLHIV on maximally-tolerated statin therapy. Evolocumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV with high cardiovascular risk. (Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia; NCT02833844).

Auteurs: Franck Boccara, Princy N Kumar, Bruno Caramelli, Alexandra Calmy, J Antonio G López, Sarah Bray, Marcoli Cyrille, Robert S Rosenson

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2020.03.025. Bijgewerkt 2026-07-03T13:27:45Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.